MX2024004443A - Promotores de estereocilina y usos de estos. - Google Patents
Promotores de estereocilina y usos de estos.Info
- Publication number
- MX2024004443A MX2024004443A MX2024004443A MX2024004443A MX2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A MX 2024004443 A MX2024004443 A MX 2024004443A
- Authority
- MX
- Mexico
- Prior art keywords
- promoters
- strc
- stereocilin
- expression product
- hair cells
- Prior art date
Links
- 102000016796 Stereocilin Human genes 0.000 title abstract 5
- 108050006373 Stereocilin Proteins 0.000 title abstract 5
- 206010011878 Deafness Diseases 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 210000003030 auditory receptor cell Anatomy 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 210000002768 hair cell Anatomy 0.000 abstract 1
- 210000004307 hair cells vestibular Anatomy 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000001720 vestibular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254930P | 2021-10-12 | 2021-10-12 | |
| US202263307484P | 2022-02-07 | 2022-02-07 | |
| US202263338605P | 2022-05-05 | 2022-05-05 | |
| PCT/US2022/046444 WO2023064388A2 (en) | 2021-10-12 | 2022-10-12 | Stereocilin promoters and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004443A true MX2024004443A (es) | 2024-07-01 |
Family
ID=85988783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004443A MX2024004443A (es) | 2021-10-12 | 2022-10-12 | Promotores de estereocilina y usos de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240401079A1 (https=) |
| EP (1) | EP4416294A2 (https=) |
| JP (1) | JP2024538076A (https=) |
| KR (1) | KR20240109294A (https=) |
| AU (1) | AU2022364798A1 (https=) |
| CA (1) | CA3235268A1 (https=) |
| IL (1) | IL312056A (https=) |
| MX (1) | MX2024004443A (https=) |
| WO (1) | WO2023064388A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020014625A1 (en) | 2018-07-13 | 2020-01-16 | Akouos, Inc. | Methods of treating non-syndromic sensorineural hearing loss |
| CN116836975A (zh) * | 2022-03-25 | 2023-10-03 | 上海玮美基因科技有限责任公司 | 一种耳蜗和/或前庭细胞特异性启动子及其应用 |
| WO2024250774A1 (zh) * | 2023-06-07 | 2024-12-12 | 苏州星奥拓维生物技术有限公司 | 耳蜗外毛细胞特异性启动子及其应用 |
| CN116925239B (zh) * | 2023-07-17 | 2024-10-18 | 苏州星奥拓维生物技术有限公司 | 双载体系统表达Otof基因的组合物和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070161031A1 (en) * | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
| WO2020014625A1 (en) * | 2018-07-13 | 2020-01-16 | Akouos, Inc. | Methods of treating non-syndromic sensorineural hearing loss |
| CA3115810A1 (en) * | 2018-10-11 | 2020-04-16 | Decibel Therapeutics, Inc. | Aav1 vectors and uses thereof for treatment of otic indications |
-
2022
- 2022-10-12 EP EP22881724.3A patent/EP4416294A2/en active Pending
- 2022-10-12 US US18/699,454 patent/US20240401079A1/en active Pending
- 2022-10-12 WO PCT/US2022/046444 patent/WO2023064388A2/en not_active Ceased
- 2022-10-12 CA CA3235268A patent/CA3235268A1/en active Pending
- 2022-10-12 AU AU2022364798A patent/AU2022364798A1/en active Pending
- 2022-10-12 KR KR1020247015287A patent/KR20240109294A/ko active Pending
- 2022-10-12 IL IL312056A patent/IL312056A/en unknown
- 2022-10-12 JP JP2024522122A patent/JP2024538076A/ja active Pending
- 2022-10-12 MX MX2024004443A patent/MX2024004443A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240109294A (ko) | 2024-07-10 |
| US20240401079A1 (en) | 2024-12-05 |
| CA3235268A1 (en) | 2023-04-20 |
| IL312056A (en) | 2024-06-01 |
| EP4416294A2 (en) | 2024-08-21 |
| WO2023064388A3 (en) | 2023-08-24 |
| JP2024538076A (ja) | 2024-10-18 |
| AU2022364798A1 (en) | 2024-05-02 |
| WO2023064388A2 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004443A (es) | Promotores de estereocilina y usos de estos. | |
| CL2023000294A1 (es) | Expresión selectiva de un transgene de tejidos | |
| CO2020004906A2 (es) | Composiciones y métodos para la eliminación de células cd117+ | |
| CL2015002066A1 (es) | Composiciones que incluye agentes para conferir carácter hidrofóbico y estabilizantes y métodos para elaborar y usar los mismos. | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| MX2022013005A (es) | Arni variante. | |
| MX391279B (es) | Anticuerpos biespecíficos contra cd3 y cd20. | |
| CL2017000515A1 (es) | Cd123 agentes enlazadores y su uso | |
| MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX388380B (es) | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. | |
| MX370624B (es) | Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso. | |
| MX390493B (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas | |
| MX2022005370A (es) | Analogos de compstatina de accion prolongada para usarse en el tratamiento de trastornos oculares. | |
| MX2019005661A (es) | Método para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
| MX2018000657A (es) | Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite. | |
| CO2017010151A2 (es) | Material de implante compuesto | |
| MX2021011598A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| CL2024002306A1 (es) | Elementos reguladores de gjb2 y usos de los mismos. | |
| PH12019550033A1 (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
| CO2021005872A2 (es) | Composiciones y métodos para la estimulación ovárica controlada | |
| AR110947A1 (es) | Tratamiento de degeneración de la retina mediante el uso de células progenitoras | |
| BR112019004639A2 (pt) | formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas | |
| CO2018003759A2 (es) | Tratamiento de la neuropatía periférica diabética usando células placentarias |